Overview

A Study to Observe the Safety and Tolerability of Paliperidone Palmitate (Invega Sustenna) in Korean Schizophrenic Patients

Status:
Completed
Trial end date:
2019-11-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of paliperidone palmitate over a 9-week period for participants with schizophrenia in Korea.
Details
Lead Sponsor:
Janssen Korea, Ltd., Korea
Treatments:
Paliperidone Palmitate